New Framework Tackles Key Controversies in ANCA Vasculitis Treatment

ANCA-associated vasculitis represents a critical autoimmune challenge where inflammation destroys small to medium blood vessels, often causing organ damage or death. While treatment outcomes have improved significantly, clinical practice remains inconsistent due to unresolved therapeutic controversies.

This comprehensive review by Greek rheumatologists systematically examines contentious areas in AAV management. Key debates include whether combining rituximab with cyclophosphamide provides superior induction therapy, the optimal role of newer treatments like avacopan and plasma exchange, and strategies for preventing disease relapse.

The authors highlight persistent challenges in determining maintenance therapy duration, appropriate steroid reduction schedules, and whether treatment can be safely discontinued in certain patients. They note that despite multiple high-quality clinical trials and international guidelines, treatment approaches vary significantly between clinicians and centers.

The review emphasizes promising developments in novel therapies that may address current treatment gaps, particularly for patients with resistant or refractory disease. These advances could transform outcomes for the most challenging cases where conventional treatments fail.

The work provides clinicians with a practical, evidence-based framework for navigating complex treatment decisions, potentially reducing practice variation and improving patient outcomes through more standardized, scientifically-grounded approaches to this serious autoimmune condition.